Mark Lawler: European Cancer Groundshot Research is a necessity, not a luxury

Mark Lawler shared a post by Irish Cancer Society on X, adding:

“Remember our often quoted work The Lancet Oncology – people who are treated in research active hospitals have better outcomes than those who are not.

European Cancer Groundshot Research is a necessity, not a luxury…”

Qouting Irish Cancer Society’s post:

“Cancer is the single biggest killer in Ireland, so why are we trailing behind other countries when it comes to access to lifesaving treatment? Thanks to the power of cancer research, 60% of people now survive cancer.”

Source: Mark Lawler/X and Irish Cancer Society/X

Dr. Mark Lawler is the Chair in Translational Cancer Genomics and the Associate Director of Postgraduate Studies at Queen’s University Belfast, Centre for Cancer Research and Cell Biology. He is also a Visiting Professor in Human Genetics and Molecular Medicine at the University of Chieti Pescara, Italy. His specialties include genetics, molecular medicine, cancer biology, drug discovery, graduate education, bioethics, science policy, art therapy, and public perception of science.